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Introduction
The scarcity of deceased donors in the United States and
the desire to obtain the best outcome for each potential
liver transplant recipient make candidate evaluation a
challenging endeavor, and centers are required to weigh a
multitude of clinical and psychosocial factors to place the
best candidates on the waiting list. Patient use of tobacco
is among these factors, and is exceedingly common, with
33.6% of liver transplant candidates self-reporting them-
selves as active or former smokers [1]. Smoking has
important clinical implications for patients, and financial
consequences for transplant centers.
We have previously shown that liver transplant candi-
dates at our institution have similar waiting list and post-
transplant survival regardless of smoking status at the
time of evaluation or transplant [1]. While smoking may
not affect the survival of potential liver candidates, the
majority of the literature suggests that smoking portends
a significant risk of cardiovascular, pulmonary, and
malignancy-related morbidity [2–8]. Patients, clinicians,
and insurance providers all have a vested interest in mini-
mizing post-transplant smoking-related morbidity.
Postoperative biliary leaks and strictures are a major
source of morbidity following deceased donor and living
donor liver transplantation. These complications occur in
18–36% of liver transplant procedures, and require com-
plex and expensive management strategies to identify,
control, and reconstitute the biliary drainage system
[9–35]. The key to preventing these complications is to
understand their driving mechanism. One potential
mechanism responsible for biliary leaks and strictures
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Summary
We sought to estimate the effect of smoking on the biliary complication rate
following orthotopic liver transplantation. We retrospectively evaluated the
records of liver transplant recipients at our center from July 1, 1999 to October
26, 2007. Using Cox proportional hazards models, we estimated the time to
the earliest biliary complication (leak or stricture) based on smoking exposure,
as active, former, or lifetime nonsmoker, adjusting for other clinical factors.
Overall, 409 liver transplant recipients were evaluated. The overall biliary com-
plication rate was 37.7% (n = 154). Biliary complications included 66 anasto-
motic leaks, 60 anastomotic strictures, and 28 nonanastomotic lesions. ERCP
was the primary diagnostic modality (n = 112). 18.1% of liver transplant recip-
ients were active smokers (n = 74) and 42.8% were former smokers (n = 175).
Active smokers were at greatest risk for biliary complications on unadjusted
analysis (P = 0.022). After multivariable adjustment, active smokers had a 92%
higher rate of biliary complication rates compared with lifetime nonsmokers
(HR 1.92, 95% CI 1.07–3.43), but no difference was noted in the rate of com-
plication resolution. Smoking clearly portends a significant risk of biliary com-
plications following liver transplantation. Smoking status should be clearly
defined when evaluating transplant candidacy and in counseling patients with
cirrhosis.
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may arise from corruption of the biliary microvasculature,
which is largely perfused by the hepatic arterial system.
Smoking is known to create a thrombogenic environment
in the vasculature, vasoconstriction and failure of oxygen
delivery. In addition, hepatic artery thrombosis is associ-
ated with the development of biliary complications
[36–39]. These deleterious effects may impede the healing
of the biliary anastomosis, leading to a leak, stricture, or
both.
In this study of over 400 liver transplant recipients over
an 8-year period at our center, we sought to understand
the effect of smoking on biliary complications following
liver transplantation. We hypothesized that active and
former smokers would have a significantly increased rate
of biliary complications compared with lifetime non-
smokers, after adjusting for other relevant clinical covari-
ates. By understanding the effect of smoking on biliary
complications following liver transplantation, clinicians
may be able to better select candidates for the procedure,
decrease overall morbidity and mortality in a vulnerable
patient population, and inform smoking cessation strate-
gies for patients and programs.
Methods
Patient cohort
We retrospectively reviewed the records of all adult
patients who underwent orthotopic liver transplantation
at our center between July 1, 1999 and October 26, 2007
with adequate smoking history. A total of 409 patients
had adequate smoking history. Pediatric, living donor,
partial graft, and combined liver/kidney transplant recipi-
ents were excluded from the analysis. No patient under-
went ABO incompatible transplants. All data were
collected from our institutional electronic medical record
and from a prospectively collected institutional transplant
database. Clinical data were collected on all transplant
recipients, including demographics, Model for End-Stage
Liver Disease (MELD) score, indication for transplanta-
tion, cold ischemia time, type of biliary anastomosis, the
use of a biliary stent at transplant, donor demographics,
donor cause of death, donor type, and cytomegalovirus
(CMV) serology and other factors.
Definition of smoking behaviors and definitions
of outcomes
Smoking status was determined from the review of all
clinical encounters the subject had at our center during
transplant evaluation up to the time of transplantation,
and was self-reported by all recipients. Likewise, smok-
ing cessation was recorded based on the self-report of
the transplant recipient. All patients in the cohort had
clearly defined smoking status based on the review of
their records. The study period spanned from the date
of liver transplant to the most recent follow-up or
death. We defined smoking behaviors in the following
manner:
Active smoker: Liver transplant recipients who were
actively smoking cigarettes within 3 months of their liver
transplant.
Former smoker: A patient with a history of smoking but
had quit at least 3 months prior to liver transplantation.
Lifetime nonsmoker: Patients who denied smoking ciga-
rettes at any point in their lifetime.
In addition, we also attempted to record the number of
pack-years of smoking for all active and former smokers.
These data were missing in 10% of active and former
smokers.
The primary outcome of interest was the first occur-
rence of a biliary complication, defined as any anasto-
motic or nonanastomotic leaks or strictures diagnosed
clinically or radiographically by endoscopic retrograde
cholangiopancreatogram (ERCP), percutaneous transhe-
patic cholangiogram (PTC), or magnetic resonance cho-
langiopancreatogram (MRCP), or through a combination
of these tests. At our center, the decision to pursue biliary
imaging for diagnostic or therapeutic purposes is based
solely on the clinical judgment of a multidisciplinary
group of transplant providers that include surgeons and
hepatologists. These studies are initiated when biliary sep-
sis or biliary obstruction is suspected based on physical
symptoms, signs, or laboratory testing. Because of the
great availability of these imaging techniques and the sig-
nificant risk in delaying diagnosis, our threshold is low in
pursuing these studies in general. In this analysis, all bili-
ary complications that occurred following liver transplan-
tation were included in the analysis until the end of
follow-up.
Statistical analysis
Our primary exposure variable was smoking behavior,
defined as active, former, or life-time nonsmoker, and
our primary outcome of interest was the time to the first
biliary complication, either leak or stricture. Patient
demographics, diagnoses, and other clinical details were
compared based on smoking behavior using analysis of
variance or chi-square where appropriate. For biliary
complications, the Kaplan–Meier method was used to
estimate event rates over time. The log-rank test was used
to compare biliary complication rates based on smoking
history. To evaluate the specific effect of smoking on bili-
ary complication outcomes in the context of other clini-
cal variables, a multivariable Cox proportional-hazards
model was constructed to risk-adjust our estimate of the
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time to the first biliary complication, with smoking
history as the primary exposure. Models were constructed
with smoking as a categorical variable based on history
and as a continuous variable based on total pack-years.
The adjustment covariates included recipient and donor
demographics, diagnosis, previous transplant, MELD
score at transplant, year of transplant, donor and recipi-
ent CMV status, coronary artery disease, diabetes mell-
itus, transplant surgeon, donor type (donation after
cardiac death vs. brain death), donor cause of death, cold
ischemia time, anastomosis type (biliary-enteric, choledo-
cho-choledochostomy), and the use of a biliary stent at
transplant. The occurrence of hepatic artery thrombosis
was also included in the model as a time-dependent
covariate, meaning the effect of hepatic artery thrombosis
on biliary complications is not present at baseline, i.e. its
effect may begin after it has occurred in the at-risk per-
iod. Secondary analyses included evaluating the effect of
smoking on the rate of biliary complication resolution
using a similar model structure. Each model was cen-
sored at death or at the end of follow-up (July 31, 2009).
Covariates were included in the model based on a signifi-
cant effect on univariate analysis or on potential biologic
plausibility.
The study was approved by the local Institutional
Review Board. stata version 10.0 (Stata Corp, College
Station, TX, USA) was used to complete all statistical
analyses. Statistical significance was defined at a P value
of 0.05.
Results
Baseline characteristics, smoking behavior, and detection
of biliary complications
The retrospective cohort was comprised of 409 liver
transplant recipients over an 8-year period at our center.
60.9% of liver transplant recipients were either active
(n = 74, 18.1%) or former smokers (n = 175, 42.8%).
Table 1 displays the clinical differences between patients
based on their smoking behaviors. Former smokers were
older than active and lifetime nonsmokers. Active smok-
ers had a higher proportion of males than the other
groups. MELD scores at transplant were similar for active,
former, and nonsmokers, but trended toward higher
MELD scores in the nonsmoking group. Only a small
minority of the patients in the cohort were transplanted
prior to 2003. There were significant differences in the
distribution of smoking behaviors by diagnosis. Active
and former smokers predominated the hepatitis, alcoholic
cirrhosis, and hepatocellular carcinoma diagnosis groups
(all, P < 0.01). Repeat transplant rates were similar across
smoking groups. CMV seropositivity prior to transplant
was similar across the cohort. With regard to donor fac-
tors, donor age was similar across the cohort, but active
smokers received a significantly higher proportion of allo-
grafts from male donors. There were no differences with
regard to the causes of donor death or donation after car-
diac death based on recipient smoking behavior. Former
smokers had higher rates of CMV-seropositive donors
compared with the other groups. Transplant-related char-
acteristics were fairly similar across groups. Cold ischemia
time, the use of biliary stents, and rates of postoperative
hepatic artery thrombosis were respectively similar,
regardless of smoking status at transplant. The biliary
anastomosis was duct-to-duct in the vast majority of all
cases, and was applied in active smokers more often than
in other groups.
At the end of follow-up, 37.7% of liver transplant cases
had a biliary complication (n = 154). Of the 154 patients
with biliary complications, 42.9% initially had anasto-
motic leaks, 39% had anastomotic strictures, and <10%
had nonanastomotic biliary lesions. Nine per cent pre-
sented with diffuse intrahepatic strictures. Table 2 dis-
plays the distribution of the initial biliary complications
and the method of diagnosis by smoking behavior. Over-
all, there were no statistically significant differences in the
types of initial biliary complications based on smoking
behavior at transplantation on univariate analysis. Anasto-
motic leaks were proportionally more common in the
active smokers, and strictures were equally distributed
across the cohort. Of the evaluations performed to diag-
nose biliary complications, 63.6% were identified by
ERCP and 31.3% were diagnosed using a PTC approach.
Nineteen patients required both ERCP and PTC, related
to failed endo-biliary stent placement. Few complications
were identified by MRCP alone, or clinical diagnosis
alone. Four complications were diagnosed during a
re-operation and a subsequent PTC was placed. One late
complication was initially diagnosed by MRCP, was sub-
sequently verified and treated with a subsequent PTC.
Active smokers were more readily identified using ERCP
than the other modalities, in comparison with the other
two groups.
Influence of smoking on biliary complication rates
following liver transplantation
Significant differences were noted in the incidence of bili-
ary complications based on smoking behavior at the time
of transplant. While active smokers made up <20% of the
cohort, more than half of them (51.4%) had developed a
biliary complication compared with 33.7% and 35.6% of
the former and nonsmoker groups, respectively (Fig. 1)
(P = 0.025). Figure 2 displays the cumulative incidence of
biliary complications over time for liver transplant recipi-
ents. Active smokers had a significantly higher rate of
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biliary complications compared with lifetime nonsmokers
(P = 0.022). Former and lifetime nonsmokers had a
relatively similar risk of biliary complications over time
(p=ns). Of the 154 biliary complications, 136 (88.3%)
occurred within 6 months of liver transplantation, seven
(4.5%) occurred between 6 and 12 months after trans-
plantation, seven (4.5%) occurred in the second year after
transplant, and an additional four (2.7%) occurred after
2 years post-transplant.
After multivariable risk-adjustment for donor, recipi-
ent, and transplant factors, active smokers had a nearly
twofold greater risk of biliary complications compared
with lifetime nonsmokers (HR 1.92, 95% CI 1.07–3.43)
(Fig. 3). Former smokers did not have a significantly dif-
ferent risk of biliary complications compared with the
lifetime nonsmokers (HR 1.05, 95% CI 0.64–1.74). When
considering smoking history as a continuous variable, an
increase in smoking burden by a single pack-year was not
Table 1. Clinical and demographic characteristics of 409 liver transplant recipients by smoking behavior at transplantation.
Variable Active smoker (n = 74) Former smoker (n = 175) Nonsmoker (n = 160) P-value
Recipient factors
Age at transplant (year) (SD) 49.3 ± 8.3 53.6 ± 7.8 48.8 ± 12.2 <0.001
Sex (% male) 54 (73.0) 123 (70.3) 84 (52.5) 0.001
Race (% black) 6 (8.6) 9 (5.3) 12 (7.8) 0.539
Mean MELD Score 20.2 ± 7.7 19.7 ± 6.7 21.7 ± 8.5 0.051
Pack-years of smoking (n) (SD) 28.8 ± 15.4 24.6 ± 17.2 0 ± 0 0.303
Year of transplant
1999 (n = 3) 0 (0) 1 (0.6) 2 (1.3) 0.586
2000 (n = 24) 5 (6.8) 11 (6.3) 8 (5.0)
2001 (n = 33) 8 (10.8) 13 (7.4) 12 (7.5)
2002 (n = 65) 7 (9.5) 28 (16.0) 30 (18.8)
2003 (n = 68) 16 (21.6) 23 (13.1) 29 (18.1)
2004 (n = 69) 16 (21.6) 28 (16.0) 25 (15.6)
2005 (n = 60) 5 (6.8) 31 (17.7) 24 (15.0)
2006 (n = 68) 13 (17.6) 32 (18.3) 23 (14.4)
2007 (n = 19) 4 (5.4) 8 (4.6) 7 (4.4)
Diagnosis
Hepatitis B/C (n = 201) 53 (71.6) 100 (57.1) 48 (30.0) <0.001
ETOH Cirrhosis (n = 102) 30 (40.5) 51 (29.1) 21 (13.1) <0.001
HCC (n = 44) 7 (9.5) 28 (16.0) 9 (5.6) 0.009
Cryptogenic (n = 46) 6 (8.1) 21 (12.0) 19 (11.9) 0.640
Other (n = 109) 4 (5.4) 30 (17.1) 75 (46.9) <0.001
Re-transplant (n = 26) 3 (4.1) 8 (4.6) 15 (9.4) 0.132
CMV status (% positive) 46 (62.2) 119 (68.0) 89 (55.6) 0.083
Donor factors
Donor age (year) (SD) 37.0 ± 16.8 37.3 ± 15.5 39.1 ± 15.7 0.764
Donor sex (% male) 56 (75.7) 130 (74.3) 95 (59.4) 0.005
Donor cause of death
Anoxia (n = 5) 1 (1.4) 3 (1.7) 1 (0.6) 0.211
Cardiovascular (n = 9) 4 (5.4) 4 (2.3) 1 (0.6)
Cerebrovascular (n = 155) 26 (35.1) 64 (36.6) 65 (40.6)
Trauma (n = 159) 24 (32.4) 67 (38.3) 68 (42.5)
Other (n = 16) 19 (25.7) 37 (21.1) 25 (15.6)
Donation after cardiac death (n = 14) 4 (5.4) 5 (2.9) 5 (3.1) 0.579
Donor CMV status (% positive) 19 (25.7) 60 (34.9) 65 (40.6) 0.034
Transplant factors
Cold ischemia time (min) 491.9 ± 144.5 493.9 ± 163.6 520.9 ± 183.9 0.312
Initial anastomosis type at a transplant
Choledochodochostomy (n = 356) 70 (94.6) 162 (92.6) 124 (77.5) <0.001
Roux-en-Y biliary-enteric (n = 49) 4 (5.4) 12 (6.9) 33 (20.6)
Other (n = 4) 0 (0) 1 (0.6) 3 (1.9)
Biliary stent in operating room (n = 115) 21 (28.4) 52 (29.7) 42 (26.3) 0.779
Hepatic artery thrombosis (n = 30) 3 (4.1) 10 (5.7) 7 (4.4) 0.111
Values within parenthesis are in percentage.
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associated with a significantly increased risk of biliary
complications. The remaining significant covariates are
displayed in Table 3. No recipient factor was significantly
predictive of biliary complication rates. Recipient factors
including age, sex, race, diagnosis, MELD score, co-mor-
bidities, and CMV status were not significantly predictive
of biliary complication rates. Each year increase in donor
age increased the risk of biliary complications by 2% (HR
1.02, 95% CI 1.01–1.03). Donor sex, cause of death,
donation after cardiac death, or donor CMV sero-positiv-
ity, respectively, were not significantly associated with
increased risk of biliary complications after multivariable
adjustment, respectively. Neither the year of transplanta-
tion nor the surgeon was significantly associated with an
increased risk of biliary complications. Cold ischemia
time was not associated with an increased risk-adjusted
biliary complication rate, when analyzed continuously or
categorically. However, hepatic artery thrombosis had a
significant effect on the risk of biliary complications – the
occurrence of this complication was associated with a
14% increase in biliary complication risk (HR 1.14, 95%
CI 1.06–1.21). The management of the bile duct at initial
transplant was also not predictive of a future biliary com-
plication – neither choledochocholedochostomy, Roux-
en-Y biliary-enteric configuration, nor temporary biliary
exteriorization was associated with increased biliary com-
plication rates post-transplant. However, the use of a bili-
ary stent significantly decreased the risk-adjusted biliary
complication rate by more than 60% (HR 0.39, 95% CI
0.22–0.67). An interaction analysis to determine the effect
of stent utilization on patients in each smoking group
revealed that stent use significantly altered the rate of
developing a biliary complication in active smokers to the
point that the biliary complication rates were similar
across all groups (active vs. nonsmokers: HR 2.60, 95%
CI 0.70–9.72, P = 0.155).
Of the 154 biliary complications noted at the end of fol-
low-up, 73.4% (n = 113) had resolved at the end of fol-
low-up. There were no significant differences in the
proportion of resolved biliary complications by smoking
status on univariate analysis (active smokers 78.9%, for-
mer smokers 71.2%, lifetime nonsmokers 71.9%,
P = 0.67). In a subgroup analysis of those with biliary
leaks or strictures, using a multivariable time-to-resolution
model, neither active smoking at the time of transplant
Table 2. Diagnostic and therapeutic approach to initial biliary complications by smoking behavior.
Type of biliary complication









(n = 57) P-value
Anastomotic leak 66 19 (50) 19 (32.2) 28 (49.1) 0.382
Anastomotic stricture 60 13 (34.2) 25 (42.4) 22 (38.6)
Nonanastomotic leak 9 3 (7.9) 4 (6.8) 2 (3.5)
Nonanastomotic strictures 5 0 (0.0%) 4 (6.8) 1 (1.8)









(n = 64) P-value
ERCP Diagnosis/Treatment 112 31 42 39 0.010
PTC Diagnosis/Treatment 55 8 25 22 0.470
MRCP diagnosis 2 0 2 0 0.261
Operative diagnosis/Surgical Treatment 7 2 3 3 0.872
Values within parenthesis are in percentage.
Figure 1 The development of biliary complications in a cohort of 409
liver transplant recipients based on smoking status. This figure displays
the clinical trajectory of 409 liver transplant recipients at our center
over an 8-year period. Eighteen per cent of liver transplant recipients
were active smokers at the time of transplantation. A greater propor-
tion of active smokers developed a biliary complication after liver
transplant compared with former and lifetime nonsmokers.
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nor other factors were associated with any significant dif-
ferences in the rate of biliary complication resolution.
Discussion
Cigarette smoking is altogether too common in the gen-
eral population, but particularly among liver transplant
candidates [1], and is associated with a significantly
increased risk of post-transplant biliary complications
after adjusting for a plethora of confounding factors.
Most biliary leaks and strictures developed relatively early
following transplant, and were related to the anastomosis.
Active smoking within 3 months of a liver transplant was
associated with the greatest risk of morbidity from the
bile duct, even after adjusting for several recipient,
donor, and transplant characteristics. Former smokers
seemed to be protected from this risk, demonstrating a
similar adjusted rate of biliary complications as that of
nonsmokers.
Several recent studies have evaluated the effect of
smoking on post-transplant outcomes, but have not
addressed biliary complications directly. We have previ-
ously demonstrated that 2-year post-transplant mortality
is similar for smokers and nonsmokers, with some differ-
ences arising in long-term survival [1]. Leithead and col-
leagues in Edinburgh have recently evaluated their
outcomes from a 4-year series of 132 liver transplant
recipients. Their work indicates an increased risk of over-
all, cardiovascular-specific, and sepsis-specific mortality
with smoking [40]. Other recent studies have demon-
strated that smoking is associated with inferior long-term
cardiovascular and oncologic outcomes following liver
transplantation [2,4,5,41–44]. With regard to periopera-
tive outcomes, smoking was also associated with increased
resource utilization and hospital charges following liver
transplantation in a series of 65 liver transplants over a
2-year period at the University of Kentucky [45]. Based
Figure 2 Biliary complication rates by
smoking status in liver transplant recipi-
ents. Using the Kaplan–Meier method,
the cumulative incidence of biliary com-
plications was significantly higher among
active smokers compared with both for-
mer smokers and lifetime nonsmokers.
Figure 3 Adjusted relative risk ratios of biliary complications by
smoking status in liver transplant recipients. After adjusting for recipi-
ent demographics, donor characteristics, diagnosis, disease severity,
and surgical factors, the risk of developing a biliary complication was
92% higher for active smokers compared with lifetime nonsmokers.
Former smokers notably had a similar risk of biliary complications as
their nonsmoking counterparts.
Table 3. Significant predictors of biliary complications following liver








Active smoker at transplant 1.92 1.07 3.43 0.028
Former smoker at transplant 1.05 0.64 1.74 0.838
Lifetime nonsmoker at transplant 1.00 Ref Ref Ref
Donor characteristics
Donor age
1 year increase 1.02 1.01 1.04 0.049
Transplant characteristics
Use of a biliary stent 0.39 0.22 0.67 0.001
Hepatic artery thrombosis* 1.14 1.06 1.24 <0.001
*Time varying covariate.
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on these reports, it is clear that smoking has significant
implications on short- and long-term postliver transplant
outcomes.
One of the most notable findings in our analysis
related to the placement of a biliary stent in the operating
room and its effect on subsequent complications. Biliary
stents were significantly protective from biliary leaks or
strictures, which has been previously reported by our
group [9]. The interaction between active smoking and
stent use revealed no significantly increased risk of biliary
complications. While our study may not have had suffi-
cient statistical power to evaluate this interaction more
precisely, the benefit noted across the entire population
in the multivariable models seems to favor a mitigating
effect of intraoperative stent placement in transplant
recipients who smoke. While we do not uniformly use
biliary stents during liver transplantation, we have seen
significant improvements in biliary complications when it
is applied and we now place an internal biliary stent in
most cases [9]. However, this practice must be further
studied in a randomized controlled fashion to assess its
prospective validity.
The biologic effect of smoking on post-transplant bili-
ary complications is not specifically understood, but is
likely related to the effects of smoking on the microvascu-
lature of the bile duct. The nicotine and tar in cigarettes
are known to be thrombogenic and cause vasoconstriction
by inhibiting endothelial nitric oxide pathways and other
processes [7–9]. Pungpapong et al. [7] have demonstrated
that smoking was associated with postliver transplant
arterial vascular complications, including hepatic artery
thrombosis. Smoking may create an environment of rela-
tive ischemia in the biliary tissue, which leads to poor or
improper healing. Based on our models, the risk of devel-
oping a biliary complication was 13% higher after hepatic
artery thrombosis occurred. Strategies to prevent arterial
vascular complications in liver transplantation may there-
fore improve the outcomes of the biliary anastomosis as
well.
Our findings are subject to some limitations. The esti-
mation of actual smoking exposure is difficult, particu-
larly in heavy smokers who have been smoking for a long
time, as it is based on self-reported data during trans-
plant-related clinical visits with a physician. In both active
and former smokers, this may lead to recall bias from
both patients and providers. Pack-year smoking history is
how we generally quantify smoke exposure clinically, but
this has not been validated for research purposes. Our
categorical definition of smoking behavior may obfuscate
any potential increased risk of biliary complications
among former smokers who quit relatively recently before
their transplant. Technical factors in creation of the bili-
ary anastomosis are also of concern. We attempted to
account for this by adjusting for the surgeon who did the
procedure, which was not significant, but it is impossible
to include extensive operative detail in an observational
study with this model design. In addition, our study
design has an inherent risk of confounding and selection
bias. We attempted to account for several sources of
bias using multivariable time-to-event analysis, which
improves any bias related to variable follow-up or the
development of new risk factors, such as hepatic artery
thrombosis, over time. It is possible that other variables
and missing data, such as donor smoking history or
incomplete smoking historical data in our cohort, may
affect our results. We were limited also by the patients
where smoking data were specifically noted in the clinical
documentation. We did not focus on the risk factors for
specific types of biliary complications, such as a predispo-
sition toward leaks or strictures. Our previous work on
this topic has clearly demonstrated a significant risk for
biliary strictures in those who previously had biliary leaks
[9]. Another limitation may be related to the classification
of stent usage. The type of stent used in the course of the
study was not uniform. The study period included an era
where we used the so-called ‘Turcotte tube’, which was a
trans-cystic duct biliary stent. We have previously shown
that these were associated with a greater leak rate versus
the internal biliary stents [9]. Despite the inclusion of
these ‘higher risk’ stents, the protective effect of stent uti-
lization is significant, suggesting that our latter stent use
– using an internal pediatric feeding tube – is extremely
effective. Similarly, the overall rates of biliary complica-
tions and hepatic artery thrombosis are notable and may
be higher than in other centers. Confidently, we feel that
the high rates are related to an aggressive approach to
diagnosis and management. We feel that early diagnosis
prevents much of the morbidity of a biliary complication.
Thus, the majority of our patients undergo a cholangio-
gram and liver ultrasound during the postoperative per-
iod. Any evidence of biliary leak or stricture intervened
upon was thus coded as a complication in the manu-
script. This approach to biliary complications probably
results in the high rates noted and should not affect the
overall conclusions of the study. With regard to hepatic
artery thrombosis, our analysis expands several years of
follow-up and our definition included early and late arte-
rial complications, which may have affected the rates
observed in the study. Within this context, however, our
study represents one of the largest and detailed treatments
of the effect of smoking on surgical complications follow-
ing liver transplantation.
The morbidity for patients with a biliary complication
is undoubtedly significant, but transplant centers and
payers may bear considerable economic hardships by
selecting smokers for liver transplantation [46]. These
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costs may arise directly from facility and professional fees
related to clinical interventions, and, in the future, may
also come from a loss of potential patient referrals. In the
US, transplant outcomes for graft and patient survival for
each center are documented and tracked by federal man-
date in order to ensure transparency and the long-term
success of clinical transplantation. Currently, complica-
tions such as biliary leaks or strictures are not tracked on
a national scale or reported to the public. It is conceivable
that surgical and other complications may contribute to
composite metrics used to evaluate center performance.
The risk for patients, centers, and payers is clearly great
in this context, and it may grow in the future.
Our study clearly demonstrates that one of the most
important interventions in pretransplant care to decrease
biliary complications following liver transplantation is
smoking cessation. While the benefits may not extend to
a mortality benefit given the already high mortality risk
in the population [1], we have demonstrated a clearly
important association between active smoking and biliary
complications, while being a former smoker seemed to
attenuate biliary morbidity risk to a great extent. Our
findings should not necessarily be used as the sole criteria
to block registration on a liver transplant waiting list, as
the decision to perform a transplant on a smoker with
cirrhosis should be based on a detailed clinical evaluation
of the individual patient and patient choice. Our studies
on this topic, as well as several well-designed retrospective
studies, do suggest that the aggressive use of smoking
cessation programmes in liver transplant centers may
have far-reaching benefits. Transplant center and payer
investment in smoking cessation initiatives for liver trans-
plant candidates seem to have significant promise in pre-
venting down-stream posttransplant complications and
achieving improved patient outcomes.
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